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CD46-mediated costimulation induces a Th1-biased
response and enhances early TCR/CD3 signaling in
human CD4+ T lymphocytes
Alejandra Sa´nchez, Maria Jose Feito and Jose´ M. Rojo
Centro de Investigaciones Biolo´gicas, CSIC, Madrid, Spain
The role of membrane cofactor protein (MCP, CD46) on human T cell activation has been
analyzed. Coligation of CD3 and CD46 in the presence of PMA or CD28 costimuli enhanced
IL-2, IFN-c, or IL-10 secretion by CD4+ T lymphocytes. The effect of CD46 on IL-10 secretion
did not require additional costimuli like anti-CD28 antibodies or phorbol esters. CD46 also
enhanced IL-2 or IFN-c secretion by CD4+ blasts. In contrast, IL-5 secretion was inhibited
upon CD46-CD3 coligation, in all the cells analyzed. These effects were independent of IL-12
and suggest that CD46 costimulation promotes a Th1-biased response in human CD4+
T lymphocytes. CD46 enhanced TCR/CD3-induced tyrosine phosphorylation of CD3f and
ZAP-70, as well as the activation of the ERK, JNK, and p38, but did not modify intracellular
calcium. The effect of specific inhibitors shows that enhanced ERK activation contributes to
augmented IFN-c and lower IL-5 secretion and, consequently, to the Th1 bias. Cross-linking
CD46 alone induced weak tyrosine phosphorylation of CD3f and ZAP-70. However, CD46
cross-linking by itself did not induce cell proliferation or lymphokine secretion, and
pretreatment of CD4+ T lymphocytes with anti-CD46 antibodies did not significantly alter
TCR/CD3 activation.
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1 Introduction
Membrane cofactor protein (MCP, CD46) is a type 1
transmembrane glycoprotein widely expressed by nu-
cleated cells [1–3]. CD46 is a complement regulatory
protein (CRP) binding C3b and C4b deposited on the host
cell, acting as a cofactor for their inactivation through
proteolytic cleavage by factor I; thus protecting the cells
from the attack by homologous complement [3, 4]. The
extracellular portion of CD46 consists of four domains
known as short consensus repeats (SCR) [also known as
complement control protein repeats (CCP)], character-
istic of proteins of the family of ‘regulators of complement
activation’ (RCA), and an alternatively spliced serine-,
threonine-, proline-rich region (STP region) [5–7]. In
addition, alternative splicing produces two possible
cytoplasmic domains (CYT-1 and CYT-2) of 16 and 23
amino acids, respectively [6, 7]. Consequently, poly-
morphisms of the STP and cytoplasmic domains
produce multiple isoforms of CD46 [6, 7].
Like other members of the RCA family, MCP also serves
as a cell receptor for human pathogens [8]. MCP binds
the hemagglutinin of several strains of measles virus (MV)
[9, 10], the pili of Neisseria gonorrhoeae and Neisseria
meningitidis [11], the M protein of Streptococcus pyo-
genes [12, 13], and human herpesvirus 6 [14].
In addition to its functions as a regulator of complement
and as a receptor of pathogenic microorganisms, CD46
possesses the potential of inducing cell signaling. In
human macrophages, CD46 ligation by MV, antibodies or
C3b can selectively inhibit IL-12 production [15], although
certain antibodies and strains of MV can enhance IL-12
production with concomitant dissociation of the SHP-1
protein tyrosine phosphatase [16]. The cytoplasmic
domains of CD46 associate with macrophage kinases
and can be tyrosine phosphorylated [17], and recent data
show that CYT-2, and not CYT-1, cytoplasmic domains
are the targets for src tyrosine kinases like Lck in Jurkat or
epithelial cells [18]. Furthermore, Wong et al. have
observed that mouse macrophages transfected with
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human CD46 possessing CYT-1, but not CYT-2, mediate
the enhanced production of nitric oxide (NO) in response
to MV infection in the presence of IFN-c, through the
production of IFN-a/b [19, 20]. These data show the
signaling potential of CD46, which is also set forth by the
CD46-dependent calcium flux induced by binding of
N. gonorrhoeae pili to human epithelial cells [21].
We have described that the mouse CRP Crry/p65 is a
costimulator for TCR/CD3-mediated activation of mouse
T lymphocytes [22]. In view of these results, we
performed the experiments described here, to analyze
the costimulatory effect of human MCP, as a type I
membrane protein with CRP function homologous to
mouse Crry/p65. CD46 augmented CD3-induced tyro-
sine phosphorylation of several cell polypeptides basic to
TCR/CD3 signaling, including the CD3 f chains and the
ZAP-70 tyrosine kinase, and enhanced the activation of
classical as well as the stress-activated mitogen-
activated protein (MAP) kinases. Furthermore, CD46 by
itself induces a low level of CD3f and ZAP-70 tyrosine
phosphorylation. We also observed that CD46 costimu-
lated human CD4+ lymphocyte proliferation and IL-2,
IFN-c, and IL-10 secretion, but not IL-5 production,
independently of IL-12 production by accessory cells.
Thus, in addition to its possible effect as a T regulatory
cell 1 (Tr1) differentiation promoter [23], CD46 might favor
a Th1 type of response, increasing IL-2 and IFN-c but not
IL-5 secretion.
2 Results
2.1 CD46 costimulation of CD4+ T cell proliferation
and cytokine secretion
To analyze the potential of CD46 as a costimulator, CD4+
T cells isolated from peripheral blood were cultured in the
presence of anti-CD3 and anti-CD46 mAb. CD3 + CD46
ligation significantly enhanced IL-2, IFN-c or IL-10
secretion when PMA (Fig. 1) or anti-CD28 antibodies
(Fig. 2) were present. Furthermore, anti-CD46 mAb
enhanced anti-CD3 mAb-induced proliferation, as de-
termined by a colorimetric assay and by cell cycle
analysis (data not show). Interestingly, CD46 clearly
enhanced IL-10 secretion, even if additional costimuli like
anti-CD28 antibodies or PMA were absent (Fig. 1, 2). In
contrast, IL-5 secretion was inhibited by coligation of
CD3 + CD46. Similar results were observed in isolated
naı¨ve CD4+ T cells or by using C3b as a CD46 ligand
(Sa´nchez et al., unpublished data).
CD46 ligands have been described to enhance or inhibit
IL-12 secretion by accessory cells [15, 16]. To discard a
role of IL-12 in the observed effects, the IL-12 p40 and
Fig. 1. CD46 ligation serves as a costimulus for CD3-induced
activation of human CD4+ T lymphocytes. Plate-bound anti-
CD46 (158.2A5, 20 lg/ml, open circles), anti-CD3 (OKT-3,
10 lg/ml, closed triangles), anti-CD3 + anti-CD46 (closed
circles), or control antibodies (open triangles) + PMA were
used to activate the cells, as indicated in the figure.
Costimulation was determined as IL-2, IL-5, IL-10, or IFN-
c secretion at 72 h of culture. Data represent the
means  SE of triplicate determinations of one representa-
tive experiment of five separate experiments.
Fig. 2. CD46 costimulation of CD3 activation in human CD4+
T lymphocytes: Effect of anti-CD28 and anti-IL-12 antibod-
ies. Cells were activated with plate-bound anti-CD46, anti-
CD3, anti-CD3 + anti-CD46, or control antibodies + anti-
CD28 antibody, as indicated in the figure. Blocking anti-IL-12
mAb was added ( ) or not (&) to the cultures. IL-2, IL-5, IL-
10, or IFN-c secretion at 72 h of culture was determined.
Data represent the means  SE of triplicate cultures of one
representative experiment of three separate experiments.
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p70 content in culture supernatants from different
experiments was analyzed by specific capture ELISA.
In all the cases, the IL-12 content was below the
detection limit of the assay (4 pg/ml, data not shown). In
addition, we also used neutralizing anti-IL-12 antibodies
under conditions previously used to inhibit IL-12-
mediated effects on lymphocyte activation [23], showing
no detectable effect of these antibodies in our system
(Fig. 2 and data not shown).
Since CD4+ T cell blasts were used to detect early
activation events or the effect of metabolic inhibitors (see
below), the effect of CD46 costimulation in these cells
was also analyzed. We observed that IL-2 and IFN-c
secretion was enhanced by CD46 (Fig. 3), although IL-2
secretion was dependent on additional costimuli like
PMA (Fig. 3) or CD28 (data not shown). Flow cytometry of
intracellular cytokines showed that this was due to an
enhanced number of cytokine-producing cells (data not
shown). As in normal, resting peripheral CD4+
T lymphocytes, IL-5 secretion was slightly inhibited upon
CD46-CD3 coligation (Fig. 3). In blasts, IL-10 secretion
was clearly lower than in CD4+ T lymphocytes, and CD46
did not enhance IL-10 secretion under the experimental
conditions tested (Fig. 3). Taken together, our results
suggest that CD46 favors a Th1 lymphokine profile in
human T lymphocytes.
2.2 Effect of CD46 on early TCR/CD3-mediated
signals
Epithelial cells stimulated by Neisseria pili undergo a
transient, CD46-dependent Ca2+ flux [21]. Since Ca2+
fluxes are an early signal of TCR/CD3 activation, we
analyzed the potential of anti-CD46 antibodies to induce
Ca2+ fluxes in human T cells or to enhance CD3-induced
calcium fluxes. Surprisingly, we detected no Ca2+ flux
induced by anti-CD46 mAb, even after cross-linking with
an anti-mouse Ig antibody (Fig. 4). Furthermore, anti-
CD46 mAb did not enhance anti-CD3 mAb-induced Ca2+
fluxes, before or after cross-linking. This experiment was
repeated several times with Jurkat cells (shown in Fig. 4),
but also with CD4+ T cell blasts, using different ratios and
concentrations of anti-CD3 and anti-CD46 antibodies as
well as different anti-CD46 mAb; always with the same
negative results (Fig. 4 and data not shown).
CD46 cross-linking has recently been shown to induce
tyrosine phosphorylation of several cell substrates in
Jurkat cells and T lymphocytes. These substrates
include p120CBL, LAT, Vav, and CD46 itself, and at least
in Jurkat cells, the tyrosine phosphorylation depends on
Lck [18, 24–26]. Since LATand Vav are substrates for the
ZAP-70 tyrosine kinase [27, 28] and ZAP-70 activation
depends on its binding to phosphorylated immunore-
ceptor tyrosine-based activation motifs (ITAM) of CD3
f chains [29, 30], we set out to perform experiments to
Fig. 3. Effect of plate-bound anti-CD46 mAb on the activation
of CD4+ T cell blasts by anti-CD3 mAb. Supernatants of cells
activated for 24 h with antibodies + PMA were used to
determine IL-2, IL-5, IL-10, or IFN-c, as shown in the figure.
Symbols as described in Fig. 1. Data represent the
means  SE of triplicate determinations of one representa-
tive experiment of four separate experiments.
Fig. 4. CD46 cross-linking by antibodies does not change
intracellular Ca2+. Anti-CD46 (158.2A5, 20 lg/ml), anti-CD3
(OKT-3, 10 lg/ml) or control antibodies were added at the
times indicated (open arrows); then a cross-linking rabbit
anti-mouse Ig antibody (20 lg/ml) was added (closed
arrows). Intracellular calcium was determined by flow
cytometry in cells loaded with Fluo 3AM and Fura RedAM.
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determine the effect of CD46 cross-linking on the
phosphorylation of CD3 f chains and ZAP-70 (Fig. 5).
As shown in this figure, cross-linking of CD46 induced
low-level tyrosine phosphorylation of both CD3f and
ZAP-70 (Fig. 5A, B; lane 2). The low-level activation of
CD3f and ZAP-70 by CD46 cross-linking fit with previous
data showing CD46-induced tyrosine phosphorylation of
LAT [26], a major cell substrate of ZAP-70. However,
CD46 had a stronger effect when cross-linked together
with CD3. Under these conditions, CD46 clearly en-
hanced CD3-induced tyrosine phosphorylation of CD3f
(Fig. 5A; lane 4) or ZAP-70 (Fig. 5B; lane 4).
2.3 Pre-incubation with CD46 ligands does not
alter CD3-mediated activation
Our results and previous data show that CD46 ligands
induce low-level tyrosine phosphorylation of different
early activation substrates including TCRf, ZAP-70, LAT,
Vav, or p120CBL in T lymphocytes (Fig. 5, [25, 26]) and
that they can also induce calcium fluxes [21]. Since these
weak signals might lead to altered (i.e. lower)
T lymphocyte activation [31, 32] contributing to patho-
gen-mediated immunosuppression, we analyzed the
effect of pre-incubation of CD4+ T lymphocytes with
CD46 ligands on TCR/CD3 activation. To do this, the
lymphocytes were cultured with anti-CD46 mAb-coated
beads for 24 h, washed and then activated with different
stimuli. Fig. 6 shows that pretreatment with anti-CD46
mAb did not significantly alter the activation of T cells, as
measured by anti-CD3 antibody-induced T cell prolifera-
tion in the presence or absence of phorbol esters or by
activation using combinations of ionomycin and phorbol
esters. Similar results were obtained when IL-2, IL-5, IL-
10, or IFN-c secretion was determined (data not shown).
2.4 CD46 costimulation of MAP kinase activation
Since we have observed that Crry, a protein functionally
related to CD46, enhanced extracellular signal-regulated
kinase (ERK) activation in mouse T lymphocytes [22], we
next examined the effect of CD46 ligation on the
activation of different MAP kinases. These included
ERK-1 and ERK-2, as well as the stress-activated MAP
kinases c-Jun N-terminal kinase (JNK) and p38/HOG
(p38), which are implicated in the regulation of different
transcription factors basic to cytokine secretion. Fig. 7A
shows that ligation of CD3 + CD46 synergized for ERK
activation, confirming recent results by Zaffran et al. [25].
Fig. 5. Effect of CD46 and CD3 ligation on the tyrosine
phosphorylation of f and ZAP-70. CD4+ blast cells were
activated for 5 min using latex microspheres coated with
antibodies (20 lg/ml anti-CD46, 10 lg/ml anti-CD3, or
control antibodies), as indicated. Post-nuclear cell lysates
were immunoprecipitated with antibodies against
f chains (A) or ZAP-70 (B). The immunoprecipitates were
separated by electrophoresis and analyzed by immunoblot
with anti-phosphotyrosine antibody and chemilumines-
cence, then stripped and reprobed with anti-f or anti-ZAP-
70 antibodies and chemiluminescence, as shown in the
figure. Figs. in the blots indicate molecular masses (Mr) in
kDa.
Fig. 6. Pre-incubation of peripheral blood CD4+ T cells with
anti-CD46 antibodies does not modify CD3-dependent or
-independent activation. Cells (106/ml) were incubated for
24 h in the presence of latex microspheres (106/ml) pre-
coated with anti-CD46 antibodies (10 lg/ml 158.2A5, ) or
control antibodies (10 lg/ml 3D3, &). Then, the cells were
washed and cultured at 105 cells/well for a further 72 h in the
presence of plate-bound OKT-3 (10 lg/ml), 10 ng/ml PDB,
and ionomycin (1 lg/ml), as shown in the figure. Data
represent the means  SE of triplicate determinations of one
representative experiment of two separate experiments.
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Furthermore, we observed that CD3 and CD46 signaling
also synergized for the activation of JNK (Fig. 7B) and p38
(Fig. 7C).
2.5 Effect of metabolic inhibitors on lymphokine
secretion
To confirm the role of MAP kinases and other activation
cascades in CD46 costimulation, the effect of inhibitors
blocking different pathways in cells activated by CD3 or
by CD3 + CD46 was analyzed. Preliminary experiments
using a 3-day culture of primary CD4+ T lymphocytes
showed that the p38 inhibitor SB203580 (10 lM) strongly
suppressed CD3- or CD3 + CD46-mediated activation,
as measured by proliferation or by IL-2 and IFN-c
secretion (data not shown). These results were in
agreement with previous data showing that inhibitors
of p38 blocked IL-2 secretion [33] or IL-2-induced
proliferation of human T lymphocytes [34], and sug-
gested that the inhibition of IFN-c secretion in primary
CD4+ T cells was secondary to these effects.
To directly analyze the effect of the inhibitor, we used
CD4+ T cell blasts, since CD46 costimulated IL-2 and
IFN-c secretion in short-term (24 h) cultures of these cells
(Fig. 3). In addition to the p38 inhibitor SB203580, we also
used inhibitors of molecules involved in different activa-
tion cascades triggered by TCR/CD3 ligation, including
PD98059, an inhibitor of MAP kinase/ERK kinase (MEK)1
blocking ERK activation; RO-31–8220, an inhibitor of
Ca2+-dependent and -independent PKC isoforms; or the
calcineurin inhibitor cyclosporin.
Inhibition of MEK by PD98059 clearly inhibited IL-2 and
IFN-c synthesis, particularly in CD46-costimulated cul-
tures (Fig. 8A, B). On the contrary, blocking ERK markedly
fostered IL-5 secretion, suggesting that ERK activation is
a strong negative regulator of IL-5 and favors IFN-c
production in this system (Fig. 8C). The p38 inhibitor
SB203580 had negligible effects on IFN-c, yet IL-2
secretion was clearly enhanced upon p38 inhibition, and
IL-5 synthesis was unaffected (Fig. 8). Inhibition of PKC
produced effects roughly similar to those of the MEK1
inhibitor PD98059, namely strong (IL-2) or partial (IFN-c)
inhibition of secretion and enhanced secretion of IL-5
(Fig. 8). The addition of the calcineurin inhibitor
cyclosporin clearly inhibited the secretion of all cytokines
analyzed, particularly IL-2 and IFN-c (Fig. 8).
3 Discussion
In a previous publication, we observed that Crry/p65, the
main CRP of mouse T lymphocytes, costimulated mouse
CD4+ T lymphocyte activation [22]. Here, we show that
CD46, a type 1 human cell surface molecule that, like
Crry, has cofactor effect for C3b and C4b inactivation by
plasma factor H, costimulates CD3-induced proliferation
and lymphokine secretion by CD4+ T cells (Fig. 1–3 and
data not shown). This confirms recent data showing the
costimulatory effect of CD46 in human CD4+
T lymphocytes [25, 26], extending the data to show that
CD46 enhances proliferation and IL-2 secretion, but also
IL-10 and IFN-c secretion (Fig. 1–3). Interestingly, the
effect of CD46 on IL-2 and IFN-c needs additional
costimuli delivered by PMA or CD28 (Fig. 1, 2), whereas
costimulation of IL-10 secretion can be also observed
without these costimuli (Fig. 1, 2), in agreement with
recent data by Kemper et al. [23]. CD46 costimulation is
selective, as it does not enhance but inhibits CD3-
induced secretion of the IL-5 Th2 lymphokine (Fig. 1–3).
Furthermore, IFN-c and IL-2 secretion are enhanced by
CD46 under conditions (i.e. in blast cells; Fig. 3) where it
Fig. 7. Effect of CD3 and CD46 ligation by antibodies on the
activation of the ERK, JNK and p38 MAP kinases. CD4+ blast
cells were activated for 5 min with anti-CD3 (OKT-3, 10 lg/
ml) and anti-CD46 (158.2A5, 10 lg/ml) mAb adsorbed to
latex beads. Post-nuclear lysates were separated by
electrophoresis and analyzed by immunoblot with antibodies
specific for active, dually phosphorylated forms of ERK (A),
JNK (B), and p38 (C) and chemiluminescence. Then, the
membranes were stripped and reprobed with antibodies to
ERK, JNK, and p38, respectively, and chemiluminescence.
Figs. in the blots indicate molecular masses (Mr) in kDa.
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does not enhance IL-10 secretion. This suggests that
CD46 favors a Th1 differentiation profile in human CD4+
T lymphocytes whenever TCR + CD28 or CD28-like
costimuli are provided (Fig. 1–3).
Recent data indicate that CD46 costimulation of IFN-c
might be dependent on IL-12 produced by accessory
cells and could be blocked by anti-IL-12 antibodies [23].
In this regard, previous results show that CD46 ligation of
human monocytes may inhibit [15] or enhance [16] IL-12
production. However, the amounts of IL-12 in our cultures
were undetectable, and blocking anti-IL-12 antibodies
had no significant effect on CD46 costimulation under the
conditions used (Fig. 2 and data not shown). Rather, our
results indicate that in the presence of TCR and CD28
ligands, CD46 might directly promote Th1 differentiation,
regardless of its effect on monocytes or other accessory
cells. However, this does not preclude an IL-10-mediated
effect of CD46 on Tr1 differentiation of distinct CD4+
subpopulations, as recently observed by Kemper et al.
[23], particularly when CD28 costimuli are absent (Fig. 1,
2). Thus, it is possible that antigen presentation by non-
professional APC expressing CD46 ligands (i.e. MV-
infected cells expressing viral hemagglutinin), but no
CD28 ligands, might favor Tr1 differentiation and immune
suppression, whereas professional APC expressing both
CD46 and CD28 ligands might favor Th1 differentiation of
effector lymphocytes and pathogen clearance.
Using human CD46-transgenic mice, Marie et al. have
recently observed that CD4+ T lymphocyte proliferation
by anti-CD3 + anti-CD46 antibodies is enhanced in
T cells expressing the short (CD46–1) but not the long
(CD46–2) cytoplasmic isoform of CD46 [24]. Unlike our
results in human lymphocytes (Fig. 1–3), in these
transgenic mice CD46–1 inhibited and CD46–2 had no
effect on IL-2 secretion, and IFN-c secretion was
significantly inhibited. Furthermore, IL-4 secretion was
not changed, and CD46–2 inhibited IL-10 secretion [24].
These differences are difficult to explain in terms of the
preferential expression of the Cyt2 CD46 isoforms by
human T cells, even if the dominant effect of Cyt1 is taken
into account [18]. Rather, they suggest differences
between human and mouse T lymphocytes regarding
their responses to CD46 costimulation.
One clear base for CD46 costimulation is its enhance-
ment of TCR/CD3-mediated signals, particularly tyrosine
phosphorylation of numerous protein substrates (Fig. 5,
[25, 26], and unpublished data). Our results showing
CD46-mediated enhancement of CD3f and ZAP-70
tyrosine phosphorylation (Fig. 5) provide a clear basis
Fig. 8. Effect of enzyme inhibitors on CD3 activation and CD46 costimulation. CD4+ T cell blasts were activated for 24 h with plate-
bound anti-CD3 (10 lg/ml OKT-3 + 10 lg/ml control antibody, left panels) or anti-CD3 + anti-CD46 antibodies (10 lg/ml OKT-3
and 10 lg/ml 158.2A5) and PMA at the concentrations indicated. IL-2 (A), IFN-c (B) and IL-5 (C) were determined in the
supernatants by capture ELISA in the presence or absence of drugs, as follows: the p38 inhibitor SB203580 (10 lM; P38); the
MEK1 inhibitor PD98059 (50 lM; MEK1); the PKC inhibitor RO-31–8220 (0.5 lM; PKC); or the calcineurin inhibitor cyclosporine A
(1 lM; CALC). Symbols as indicated in the figure. Cytokine content in cultures activated with anti-CD46 mAb alone or with control,
irrelevant antibodies was below the detection limits of the assay (2 U/ml IL-2, 0.6 ng/ml IFN-c, 1 pg/ml IL-5) and are not shown.
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to previously observed effects, since the substrates
(p120Cbl, LAT, and Vav) identified so far as being
phosphorylated upon CD46 cross-linking or CD3-CD46
co-cross-linking [25, 26] are substrates of ZAP-70 [27,
28].
Our results show that CD46 costimulation enhances the
stress-activated kinases JNK and p38 (Fig. 7) and
confirm previous data showing that CD46 enhances
the activation of the MAP kinase ERK (Fig. 7, [25]). The
effect of the MEK inhibitor PD98059 on lymphokine
secretion (Fig. 8) shows that ERK activation is important
to the enhanced IL-2 and IFN-c secretion induced by
CD46, but also to the lower secretion of IL-5. Thus, ERK
activation is a major contribution to the Th1-biased
secretion pattern observed upon CD46 costimulation.
Intriguingly, p38 activation has no significant effect on
IFN-c (Fig. 8). This is in contrast with data from mouse
T cells showing p38 dependence of IFN-c activation [35].
Since IL-12-induced IFN-c production is dependent on
p38 [36], the differences might stem from the IL-12
independence of the effect of CD46 in our system (Fig. 2).
Unlike primary T cells, where p38 inhibitors inhibited
proliferation and IL-2 secretion in a 3-day activation
assay ([33] and our own unpublished data), inhibition of
p38 clearly enhanced IL-2 secretion in a short-term
culture of CD4 T cell blasts, pointing to major differences
in activation between these experimental systems.
As in other leukocytes, CD46 cross-linking itself can
induce some signaling in T lymphocytes. Thus, CD46
induces low-level tyrosine phosphorylation or activation
of different substrates including CD3f and ZAP-70
(Fig. 5), as well as LAT [26], Vav, Rac, and ERK [25], an
effect that might produce lower responses upon TCR/
CD3 activation. However, our results show that pre-
incubation of T lymphocytes with anti-CD46 antibodies
does not significantly inhibit subsequent CD3-mediated
activation of T cells, even under suboptimal activation
conditions (Fig. 6 and data not shown).
Unlike data obtained in epithelial cells using Neisseria pili
as CD46 ligands [21], we have not detected a calcium rise
upon CD46 cross-linking by antibodies in human T cells
(Fig. 4 and data not shown). The reason for these different
results is not clear, although Neisseria pili might bind
CD46 as well as other cell surface molecules contributing
to the CD46-dependent calcium rise, an effect that is
difficult to conceive when specific anti-CD46 mAb are
used as ligands.
In summary, CD46 is a costimulatory molecule with the
potential to bias T cell differentiation towards a Th1 (this
paper) or a Tr1 phenotype [23]. These different capa-
bilities might underlie the success or failure in mounting
an effective immune response to pathogens directly or
indirectly binding CD46.
4 Materials and methods
4.1 Antibodies and other reagents
The following mouse mAb were used: OKT-3 (anti-CD3),
OKT-4 (anti-CD4), OKT-8 (anti-CD8), OKM1 (anti-CD11b),
L243DR (anti-human HLA-DR), and 158–2A5 (mouse IgG1
anti-human CD46, a kind gift of Dr. J. Vives, Hospital Clı´nic i
Provincial, Barcelona, Spain). 158–2A5 bound a site in CD46
overlapping or close to the sites of C3 and C4 binding, as
judged by flow cytometry assays showing enhanced C’
deposition on cell surfaces (data not shown). 3D3, a
clonotypic mouse IgG1 mAb, was used as filling antibody.
All antibodies were used as protein A- or protein G-purified
preparations of hybridoma supernatants. Anti-CD28
(CD28.2) and a neutralizing anti-human IL-12 p40/p70
(C8.6) antibody were from Becton Dickinson. Horseradish
peroxidase (HRP)-coupled anti-phosphotyrosine mAb PY-20
was obtained from Amersham Pharmacia Biotech (Little
Chalfont, GB).
Rabbit anti-ZAP-70 antibodies were obtained by immuniza-
tion with a fusion protein of glutathione-S-transferase (GST)
and a fragment coding the sequence between residues 266
and 344 of mouse ZAP-70. Rabbit anti-f antibodies were
obtained by immunization with a synthetic peptide corre-
sponding to residues 132–144 of mouse f chains coupled to
ovalbumin. Anti-ZAP-70 or anti-f antibodies were purified by
affinity chromatography over the immunizing protein or
peptide coupled to Sepharose. For immunoprecipitation,
the anti-ZAP-70 or anti-f antibodies were coupled to CNBr-
Sepharose. Rabbit anti-active-ERK antibodies were from
New England Biolabs (Beverly, MA). Rabbit anti-active-JNK,
and anti-active-p38 antibodies were from Promega (Madi-
son, WI). Rabbit anti-ERK, anti-JNK1 and anti-p38 anti-
bodies were from Santa Cruz Biotechnology (Santa Cruz,
CA). FITC-conjugated goat anti-mouse IgG was from
Calbiochem (San Diego, CA). HRP-conjugated anti-rabbit
Ig antibodies were from Sigma Chemical Co. (St. Louis,
MO).
The calcineurin inhibitor cyclosporin A, PMA and phorbol di-
butyrate (PDB) were from Sigma. The MEK1 inhibitor
PD98059, the p38 inhibitor SB203580, the PKC inhibitor
RO-31–8220, and ionomycin were from Calbiochem.
4.2 Cells and cell lines
The Jurkat T cell lymphoma was maintained in RPMI 1640
medium supplemented with 200 mM L-glutamine, 510–5 M
2-ME, 10 % heat-inactivated FBS and antibiotics (culture
medium).
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CD4+ T lymphocytes were isolated from peripheral blood of
normal, healthy donors that had been informed of the
purposes of the study and after their written consent, or from
buffy coats of anonymous normal donors. The study followed
institutional and national guidelines and had been approved
by the Ethics Review Board of the institution. Mononuclear
cells were obtained by Ficoll-Hypaque centrifugation,
washed and incubated with anti-CD8 (OKT-8), anti-CD11b
(OKM1), and anti-DR antibodies (L243DR) in the cold. After
washing, CD4+ cells were obtained by negative selection by
passing the cell suspension over mouse Ig-anti-Ig columns
[37]. The cells in the eluate were >95% CD3+ CD4+, as
determined by flow cytometry. To obtain CD4+ T cell blasts,
CD4+ lymphocytes (106/ml) were activated with PHA (1 lg/
ml) in the presence of syngeneic, mitomycin C-treated
peripheral blood mononuclear cells (2105/ml) and human
recombinant IL-2 (100 U/ml). After 48 h of culture, the cells
were washed and expanded for a further 3 days in the
presence of 10 U/ml IL-2, washed and used for activation.
The cells obtained were >98% CD4+, as determined by flow
cytometry.
4.3 Cell culture and activation
For short-term activation, the antibodies were adsorbed to
polystyrene beads (5 lm diameter, Polysciences) by over-
night incubation at 4C in PBS. Adsorption to beads was
performed by incubating 4107 beads/ml with 10 lg/ml
anti-CD3 mAb and 10 lg/ml anti-CD46 mAb, with 3D3 being
used as filling antibody. The cells to be activated were
washed twice in serum-free culture medium, resuspended in
the same medium at 108 cells/ml and mixed 1:1 with washed
antibody-coated polystyrene beads. After incubation for
5 min at 37C, 1 ml of ice-cold PBS, 500 lM EDTA, 200 lM
sodium orthovanadate was added, and the cells were spun
2 min at 1,000g before lysis. Where indicated, cells (107/ml
in culture medium) were incubated with metabolic inhibitors
for 30 min at 37C, washed and then activated as described.
Activation of CD4+ T lymphocytes or CD4+ T cell blasts for
proliferation or lymphokine secretion was performed by
incubation (105 cells/well in 0.2 ml of culture medium) in flat-
bottom 96-well culture plates previously coated with anti-
CD3 and anti-CD46 antibodies, for the times specified in
Sect. 2. To determine lymphokine secretion, 0.1 ml of
supernatant was taken after 72 h or 24 h of culture for
lymphocytes and blasts, respectively. Proliferation was
determined by a colorimetric method, as described [22].
The data of one representative experiment out of at least
three are shown.
4.4 Intracellular calcium
Intracellular calcium was determined by flow cytometry. Cells
(2.5106–5106/ml) were loaded with Fluo 3AM (4 lM,
Molecular Probes) and Fura RedAM (10 lM, Molecular
Probes) in 0.1% Pluronic F127 by incubation for 45 min at
37C and washed with HBSS + 1% FCS. The cells (5106/
ml) were analyzed by flow cytometry, and anti-CD3 (5 lg/ml),
anti-CD46 (50 lg/ml), or control antibodies were added as
indicated. Then, affinity-purified rabbit anti-mouse Ig anti-
bodies (20 lg/ml) were added as cross-linkers, as shown in
Sect. 2. The data was expressed as ratio of green
fluorescence (FL1) to red fluorescence (FL2).
4.5 Cell lysis and immunoprecipitation
Cells were lysed on ice for 30 min at 2107 cells/ml with
50 mM Tris/HCl pH 7.6, 10 mM 3-[(3-cholamido propyl)-
dimethyl ammonium]-1-propane sulfonate (CHAPS),
150 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 10 lg/ml apro-
tinin, 10 lg/ml leupeptin, 1 mM PMSF, and 1 mM NaVO4.
Post-nuclear lysates were used for immunoblot or precleared
by rotation with Sepharose-coupled normal rabbit IgG (1 h at
4C, 20 ll of packed beads/107-cell lysate). Precleared
lysates from 5106–10106 cells were immunoprecipitated
with 15 ll of Sepharose-conjugated anti-f or anti-ZAP-70
antibody (2 h rotation at 4C). Immunoprecipitates were
washed five times with 50 mM Tris/HCl pH 7.6, 2 mM
CHAPS, 150 mM NaCl, 200 lM NaVO4, and used for
immunoblot.
4.6 Immunoblot
For immunoblot of cell lysates, 10 ll (equivalent to
2105 cells) were mixed 1:1 (vol/vol) with 2 reducing
SDS Laemmli sample buffer. Immunoprecipitates were
extracted with 1 reducing sample buffer. The samples
were boiled for 5 min and separated by SDS-PAGE in 10%
acrylamide gels. Proteins were transferred to PVDF mem-
branes (Immobilon-P, Millipore), and the membranes were
blocked for 2 h at room temperature with 1% BSA in TBST
containing 200 lM sodium orthovanadate for phosphoty-
rosine blot or 3% non-fat dry milk in TBST, 200 lM sodium
orthovanadate. The membranes were washed with TBST,
incubated overnight in the cold with anti-active-MAP kinase
antibodies or HRP-coupled anti-phosphotyrosine antibodies
in 1% BSA in TBST, washed with TBST and visualized using
the supersignal West Pico chemiluminiscent substrate
(Pierce) for phosphotyrosine determination. For detection
of anti-active-MAP kinase antibodies, the membranes were
incubated for a further 2 h at room temperature with HRP-
conjugated anti-rabbit IgG in 1% non-fat dry milk in TBST,
washed and developed with chemoluminiscent substrate as
above. Then, the membranes were washed, stripped and
reprobed with antibodies specific for MAP kinases, ZAP-70,
or f, and then with HRP-conjugated anti-rabbit or anti-mouse
IgG in 1% non-fat dry milk in TBST.
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4.7 Cytokine detection by ELISA
IL-2, IL-5, and IFN-c were detected in culture supernatants
by specific capture ELISA. For capture of IL-2, 534.411
(mouse IgG1, Becton Dickinson) was used, and biotinylated
B33-2 (Mouse IgG1, Becton Dickinson) was used for
detection of IL-2. The IL-5 ELIpair kit (Diaclone Research,
Besanc¸on, France) was used for IL-5 capture ELISA. NIB42
and biotinylated 4S.B3 (mouse IgG1, Becton Dickinson) were
used as capture and detection antibodies, respectively, in
IFN-c assays. For IL-10, the antibodies JES3-19F1 and
JES3-12G8 (rat IgG2a, Becton Dickinson) were used for
capture and detection. The assays were performed accord-
ing to the instructions of the supplier and developed using
streptavidin-HRP (Amersham) and Sigma-fast o-phenylene-
diamine substrate (Sigma). Content was calculated from
reference standard curves set up with recombinant cyto-
kines.
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